Travere Therapeutics Inc (NASDAQ: TVTX) is 5.45% higher on its value in year-to-date trading and has touched a low of $5.12 and a high of $20.33 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The TVTX stock was last observed hovering at around $18.47 in the last trading session, with the day’s loss setting it -0.1%.
Currently trading at $18.37, the stock is 2.40% and 0.84% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.88 million and changing -0.54% at the moment leaves the stock 52.32% off its SMA200. TVTX registered 99.02% gain for a year compared to 6-month gain of 87.26%. The firm has a 50-day simple moving average (SMA 50) of $18.2162 and a 200-day simple moving average (SMA200) of $12.060025.
The stock witnessed a 4.97% loss in the last 1 month and extending the period to 3 months gives it a 1.77%, and is 1.55% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.12% over the week and 4.83% over the month.
Travere Therapeutics Inc (TVTX) has around 380 employees, a market worth around $1.60B and $203.45M in sales. Profit margin for the company is -172.78%. Distance from 52-week low is 258.79% and -9.64% from its 52-week high. The company has generated returns on investments over the last 12 months (-117.93%).
with sales reaching $70.84M over the same period.The EPS is expected to shrink by -144.00% this year, but quarterly earnings will post 58.30% year-over-year. Quarterly sales are estimated to grow 57.22% in year-over-year returns.
Travere Therapeutics Inc (TVTX) Top Institutional Holders
The shares outstanding are 87.03M, and float is at 85.88M with Short Float at 10.15%.
The top institutional shareholder in the company is BLACKROCK INC. with over 7.64 million shares valued at $62.84 million. The investor’s holdings represent 9.8642% of the TVTX Shares outstanding. As of 2024-06-30, the second largest holder is ARMISTICE CAPITAL, LLC with 7.5 million shares valued at $61.65 million to account for 9.6774 of the shares outstanding. The other top investors are DEEP TRACK CAPITAL, LP which holds 7.37 million shares representing 9.5096% and valued at over $60.58 million, while VANGUARD GROUP INC holds 8.5416 of the shares totaling 6.62 million with a market value of $54.41 million.
Travere Therapeutics Inc (TVTX) Insider Activity
The most recent transaction is an insider sale by Inrig Jula, the company’s CHIEF MEDICAL OFFICER. SEC filings show that Inrig Jula sold 2,066 shares of the company’s common stock on Jan 03 ’25 at a price of $19.10 per share for a total of $39461.0. Following the sale, the insider now owns 59883.0 shares.
Travere Therapeutics Inc disclosed in a document filed with the SEC on Jan 06 ’25 that Inrig Jula (CHIEF MEDICAL OFFICER) sold a total of 440 shares of the company’s common stock. The trade occurred on Jan 06 ’25 and was made at $18.76 per share for $8254.0. Following the transaction, the insider now directly holds 59443.0 shares of the TVTX stock.
Still, SEC filings show that on Dec 26 ’24, Calvin Sandra (SVP, CHIEF ACCOUNTING OFFICER) disposed off 15,000 shares at an average price of $17.22 for $0.26 million. The insider now directly holds 54,927 shares of Travere Therapeutics Inc (TVTX).
